Back to Top

"One of today's leaders in investor relations and shareholder services"

Category Archives: Client News

Cannabis Consortium Secures Loan for $1 Million

  • The loan is non-convertible
  • The loan term is 1 year
  • The funds will be used to pay down existing debt

COCONUT CREEK, Fla., June 22, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Bahamas Development Corporation (OTCPINK:BDCI) subsidiary company Global Consortium, Inc., f/k/a Cannabis Consortium, has secured a non-convertible loan for $1 million dollars from the same party that invested $1 million dollars in the previously announced private placement.

The loan is non-convertible, and will not cause any dilution for Global Consortium, Inc. The Note has a term of 1 year and carries an interest rate of 6%. Funding of the loan will be completed on or before July 3, 2018, and funds will be disbursed to the parties on the same day.

Global Consortium will use the funds to pay down the note for $1.5 million owed on the Indulge Oils transaction. An agreement has been entered into with the Company’s President Tom Roland, to extend a portion of the final payment of $500,000 until the end of July 2018. A short-term note for 30 days will be entered into between Global Consortium Inc. and Mr. Roland.

After the July 4th break, Global will report on its revenue figures for the period ending June 30, 2018.

Bahamas Development Corporation, in compliance with SEC regulations, may in the future use social media outlets like Facebook or Twitter and its own website to announce key information in compliance with Reg FD.

Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, estimates of services and equipment markets, release of corporate apps, growth of platform, target markets, product releases, product demand and, business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also consider that any investment in securities is at risk.

Details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure on otcmarkets.com.

For additional information about this release please contact:

Investor Relations:

Matt Dwyer
matt@cannabisconsortium.net
www.cannabisconsortium.net
954-906-0098

Posted in Client News| Tagged , |

BriaCell to Hold Conference Call on Key Clinical Findings; Activities

BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient enrollment acceleration.

Dr. Williams, BriaCell’s President & CEO, will be available to answer questions following the presentation on:

Date: June 28, 2018 at 11:00 AM ET

Dial-In Numbers:
Canada: 1-647-722-6839
United States: 1-303-248-0285
Access Code: 5147677

Webinar Access (at the time of event): http://www.readytalk.com/join (Access code: 5147677)

Key Highlights

  • The latest updates on BriaCell’s Phase IIa clinical study of its lead candidate, Bria-IMT™, in advanced breast cancer (NCT03066947).
  • Exciting progress in the development of Bria-OTS™, BriaCell’s first off-the-shelf personalized immunotherapy treatment for advanced breast cancer.
  • Promising early insights into the novel mechanism of action of Bria-IMT™, also referred to as SV-BR-1-GM. This may explain the impressive early clinical data including tumor shrinkage observed in some patients with advanced metastatic breast cancer, and form the path for the development of Bria-DX™, BriaCell’s Companion Diagnostic Test.
  • Recent acceleration in the patient enrollment due to increased number of clinical sites, and expected interim data in 2H2018.
  • The latest on the rollover trial (NCT03328026) with Bria-IMT™ in combination with other immunotherapies.
  • Advancements in BriaCell’s R&D pipeline.
  • Proposed plans for strategic alliances.

“We are very excited to have hit several important milestones for BriaCell and want to share our plans and the key objectives coming up. Our development of a novel personalized targeted immunotherapy that is off-the-shelf without the costs associated with other personalized approaches positions BriaCell to revolutionize the treatment of advanced breast cancer patients. This novel targeted approach and the excellent safety profile we have seen to date should make BriaCell an attractive collaborator for a large number of large and medium sized pharmaceutical companies focusing on immuno-oncology. We will continue to work tirelessly to improve patient outcomes in the fight against this deadly disease, ” stated Dr. Williams, BriaCell’s President & CEO.

We welcome all our shareholders and prospective investors, partners and patients to attend the Company’s corporate update.

The presentation will be available for download at http://briacell.com/investor-relations/presentations/.

The Company also announces that an analyst’s research report has been released by the US-based consulting firm, RB Milestone Group, LLC (“RBMG”). The report provides an in-depth overview of the Company’s product candidate and clinical development updates. It also provides an investment rationale, SWOT analysis, and an overview of the dynamics of the oncology sector trends.

A copy of the research report can be accessed by visiting the homepage of BriaCell’s corporate website (http://briacell.com/category/recent-events/) or by directly contacting Trevor Brucato, Managing Director at RBMG (tbrucato@rbmilestone.com).

For further information, please contact the Farrah Dean, Manager, Corporate Development at Phone: 1-888-485-6340.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. Immunotherapy has come to the forefront in the fight against cancer because it uses the body’s own immune system in recognizing and selectively destroying cancer cells while leaving normal cells intact. In addition, immunotherapy is also considered to be a more potent approach than chemotherapy, and has the potential to prevent cancer recurrence.

Bria-IMT™ (SV-BR-1-GM), the Company’s lead product candidate, is derived from a specific breast cancer cell line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system. BriaCell believes that Bria-IMT™ helps the body to recognize and kill tumor cells by activating both T cells that directly attack tumor cells, and B cells that produce anti-tumor antibodies.

The results of two previous proof-of-concept clinical trials (one with the precursor cell line not genetically engineered to produce GM-CSF and one with Bria-IMT™) produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial reduction in tumor size and volume in these sites, including sites in the breast, the lung, soft tissues, and even the brain. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™ in patients with advanced breast cancer. In this trial, to date, Bria-IMT™ treatment has been safe with instances of tumor reduction observed. This trial is listed in ClinicalTrials.gov as NCT03066947. The trial is being conducted along with the co-development of BriaDX™, the Company’s companion diagnostic test, to be able to predict the patients who will likely benefit the most from Bria-IMT™ treatments. Additionally, the FDA recently approved a rollover combination study of Bria-IMT™ with pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company]. This study permits continuation of the Bria-IMT™ treatment for patients in the ongoing Phase I/IIa trials who stop responding to the treatment. The rollover trial is listed in ClinicalTrials.gov as NCT03328026.

Based on our observation of superior tumor shrinking responses in the patients who shared certain HLA types with Bria-IMT™, BriaCell is developing Bria-OTS™, an off-the-shelf personalized Immunotherapy, for advanced breast cancer. Bria-OTS™ includes a set of cell lines, each being similar to Bria-IMT™, which are being engineered to express various pre-manufactured HLA types. With only 15 different HLA types, Bria-OTS™ cell line combinations are expected to cover over 90% of the United States’ population. BriaCell expects to use BriaDX™ to determine the HLA types of patients, and subsequently select one or two Bria-OTS™ cell lines with matching alleles to be administered to the patient. This should produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics currently used for other personalized immunotherapies. In essence, Bria-OTS™ should provide a personalized treatment without the need for personalized manufacturing.

BriaCell’s small molecule program includes the development of novel, selective protein kinase C delta (PKCδ) inhibitors which have shown potent activity in a number of pre-clinical models of several different cancer indications as well as fibrotic diseases.

For additional information on BriaCell, please visit our website: http://briacell.com.

About RB Milestone Group, LLC

RB Milestone Group, LLC (“RBMG”) is a US-based capital markets consulting firm with offices in Stamford, CT and New York, NY. RBMG provides advisory services in corporate strategy, investor awareness, business development, market intelligence and research to small and venture-stage companies globally. RBMG is known for its deep-rooted contacts amongst high net worth individuals, small funds, family offices, brokers and strategics within the United States. Staff specialists have diverse sector knowledge centered on capital markets. Website: www.rbmilestone.com.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340

Posted in Client News| Tagged |

S. Parikh Mars, CEO of Progressive Care Inc., Provides Updates and Insights into Recent Events in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, June 21, 2018 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. and Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, announced today that the Company is featured in a new audio interview at SmallCapVoice.com, Inc.

The interview outlining RXMD’s current news and efforts can be heard at https://smallcapvoice.com/blog/6-20-18-smallcapvoice-interview-with-progressive-care-inc-rxmd/.

S. Parikh Mars, CEO of Progressive Care Inc., called in to SmallCapVoice.com, Inc. to answer shareholder questions, discuss the impact of recent news about CVS entering the prescription delivery market, provide an update on several fronts and more. Recently, RXMD announced further growth year-over-year in both revenue and number of prescriptions filled for May 2018. The May sales figures come on the heels of some significant company announcements including the launch of a nationwide opioid marketing campaign, the purchase and installation of a new TCGRx pouch packaging system and the initial steps in developing a proprietary tele-pharmacy software.

For more information about Progressive Care, please visit the company’s website.

Connect and stay in touch with us on social media:

Progressive Care Inc.
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS

PharmCo, LLC
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx

About Progressive Care, Inc.

Progressive Care Inc. (RXMD), through PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management (MTM), prescription medications to long term care facilities, and health practice risk management.

About SmallCapVoice.com. Inc.

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and its services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:
Tory Patterson, CMW Media
Public Relations Consultant
Tory@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
Armen Karapetyan, Progressive Care
Senior Advisor Business Development
Armen@progressivecareus.com
www.progressivecareus.com
www.pharmcopharmacy.com

For SmallCapVoice.com

Stuart T. Smith
512-267-2430
info@smallcapvoice.com

Source: SmallCapVoice.com

Posted in Client News| Tagged |

John Sprovieri, President and CEO and Lee Odom, Director of Investor Relations and Business Development for Auscrete Corporation Provide Updates and Insights into Recent Events in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, June 21, 2018 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. and Auscrete Corporation (OTC Pink:ASCKD) (the “Company”) announced today that the Company is featured in a new audio interview at SmallCapVoice.com, Inc.

The interview outlining ASCKD’s current news and efforts can be heard at https://smallcapvoice.com/blog/6-20-18-smallcapvoice-interview-with-auscrete-corporation-asckd/

John Sprovieri, President and CEO and Lee Odom, Director of Investor Relations and Business Development for Auscrete Corporation called in to SmallCapVoice.com to discuss the efforts for the Company so far in 2018, how funds from their recent capital raise will propel the operations for the company, the goals for 2018, and much more. Recently, in an update to their shareholders, Auscrete addressed the reverse split and the management moves made to ensure the future value of the Company and its capital structure. Currently, the stock symbol has D at the end of it in reference to the recent split. By the company’s calculation, that D will be removed by July 5th, 2018.

In the interview, Mr. Odom stated, “In regard to our up-listing efforts, we have already been in talks with OTCMarkets.com about the process and they are getting the paperwork to us now, and in the next few days we will start the paperwork process. We are excited to get our stock and our company in front of a new audience of investors and this up-listing will facilitate that happening.”

To stay in the know about all things Auscrete Corporation, interested parties are encouraged to visit http://auscreteblog.com/ early and often!

About Auscrete Corporation

Auscrete Corporation (ASCK) is a building products manufacturer and constructer of “GREEN” energy efficient housing and commercial structures built from Auscrete developed lightweight hybrid concrete/insulation wall and roof panels. Structures built of this medium have very low maintenance and, being concrete, are highly resistant to insects and mold. They have considerable mass and are highly resistant to hurricane forces and earth tremors. They will not catch fire and burn. Auscrete has established their Flagship Facility in Goldendale, WA.

About SmallCapVoice.com. Inc.

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and its services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/

Safe Harbor Statement:

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the issuance of the company’s pending patent application, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Contact

Lee Odom
VP of Business Development
Director of Investor Relations
Email: Lee@auscretehomes.com
Phone: 305 853 8404
Website: www.auscretehomes.com

For SmallCapVoice.com

Stuart T. Smith
512-267-2430
info@smallcapvoice.com

Source: SmallCapVoice.com

Posted in Client News| Tagged |

Cannabis Consortium Partners With Green Matter Holdings and Moves Forward With 15-Acre Hemp Test

  • Planting 24,640 industrial hemp clones in 3 strains
  • The partners retained a local consultant to assist in overseeing the test
  • Executed documents and a picture of the seedlings has been posted to OTCMarkets.com

COCONUT CREEK, Fla., June 18, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Bahamas Development Corporation (OTCPINK:BDCI) subsidiary company Global Consortium, Inc., dba Cannabis Consortium has partnered with Green Matter Holdings, LLC and moved forward with the 15-acre industrial hemp farm test.

The partners have hired a local company to supply the farmer with 24,640 industrial hemp clones at the cost of $5.00 per clone in 3 different strains to be planted on the test site.

The farmer is responsible for planting, caring and harvesting the crops. The partners will pay the farmer a total of $100,000 in between the time of the execution of the agreement and harvesting the crops.

The local company has been retained as a consultant to supply the clones and help oversee the planting, growing, and harvesting of the industrial hemp.

The partners will share the expenses 50/50 associated with the planting, irrigation, weed control, drip line, mulch system, filters, mainline, mulch plastic components, clones, fertilizer and the harvesting expense of the industrial hemp.

The farmer estimates two crop grows annually. If the initial test is proven, the next step is to plant up to 600 acres of hemp.

Originally we were led to believe there were as many as 800 acres available to plant. The actual total available acreage after the test is 600 acres. If all 600 acres are planted, the estimated gross revenue expected to accrue annually is $120,000,000 minus $20,000,000 in operating expenses, resulting in a net of $100,000,000.

Bahamas Development Corporation, in compliance with SEC regulations, may in the future use social media outlets like Facebook or Twitter and its own website to announce key information in compliance with Reg FD.

Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, estimates of services and equipment markets, release of corporate apps, growth of platform, target markets, product releases, product demand and, business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also consider that any investment in securities is at risk.

Details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure on otcmarkets.com.

For additional information about this release please contact:

Investor Relations:

Matt Dwyer
matt@cannabisconsortium.net
www.cannabisconsortium.net
954-906-0098

Posted in Client News| Tagged |

Cannabis Consortium’s Partner Purchases 25,000sq.ft Building With Multiple Licenses

  • Building contract has been signed and escrow funded
  • Building comes with 4 cannabis licenses
  • Multiyear tenant to pay $30,000 a month in rent
  • Option to purchase the remaining 38,000 square feet

COCONUT CREEK, Fla., June 14, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire – Bahamas Development Corporation (OTCPINK:BDCI) subsidiary company Global Consortium, Inc. dba Cannabis Consortium Partners have placed a 25,000 square feet building in Northern California under contract for $4 million dollars.

The escrow account has been funded and Cannabis Consortium and its Partners have been issued a lease to move in prior to closing and begin operations.

The building has been granted 4 licenses (2 manufacturing, 1 cultivation, and 1 distribution) a tenant has been lined up to rent 20,000 square feet for cultivation. The tenant has agreed to pay $30,000 a month in rent and a portion of the proceeds from each harvest.

Cannabis Consortium and its Partners will utilize 5,000 square feet and construct a mezzanine for an additional 1,500 square feet. This space will be used for manufacturing oils and infusing edibles.

An option has been granted on the other section (38,000 square feet) of the building for $5 million dollars that is currently rented. The tenant is looking to relocate. The building has been approved for subdivision into condos and the other section of the building would allow for more than 20 licenses to be granted and those can be leased with each condo.

The City of Sacramento held a series of meetings to curtail the issuance of additional licenses which is why Global Consortium withdrew its offer to purchase the building. The owner was not willing to see if a license would be granted before Closing.

The new building with the 4 active cannabis licenses would command $9 million dollars. The full building with all the various licenses it could obtain would be worth several times that amount.

Bahamas Development Corporation, in compliance with SEC regulations, may in the future use social media outlets like Facebook or Twitter and its own website to announce key information in compliance with Reg FD.

Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, estimates of services and equipment markets, release of corporate apps, growth of platform, target markets, product releases, product demand and, business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also consider that any investment in securities is at risk.

Details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure on otcmarkets.com.

For additional information about this release please contact:

Investor Relations:

Matt Dwyer
matt@cannabisconsortium.net
www.cannabisconsortium.net
954-906-0098

Posted in Client News| Tagged |